Colitis

5-HTP is the immediate precursor to serotonin, directly increasing central serotonin synthesis after crossing the blood-brain barrier. Multiple human clinical trials and preclinical studies document its role in modulating serotonin and, when balanced with dopamine precursors, broader monoamine balance. Evidence covers depression, anxiety, sleep disorders, and myoclonus.

Acetyl-L-Carnitine (ALCAR) donates acetyl groups for acetylcholine synthesis and raises brain acetylcholine levels. Clinical trials in Alzheimer's disease and cognitive decline show measurable improvements in cholinergic function. It also upregulates dopamine D1 receptors and supports mitochondrial energy for neurotransmitter-producing neurons.

Acetyl-L-Tyrosine (NALT) is a more soluble form of L-tyrosine, the direct amino acid precursor to dopamine and norepinephrine. It supports catecholamine neurotransmitter synthesis particularly under demand conditions. Human studies on L-tyrosine show cognitive benefits under acute stressors consistent with dopamine/norepinephrine replenishment.

Agmatine is an endogenous neuromodulator derived from arginine decarboxylation, found in mammalian brain, acting at NMDA glutamate, imidazoline, serotonin 5-HT2A, nicotinic, and alpha-2 adrenergic receptors. It functions as a co-transmitter modulating multiple neurotransmitter systems. Small human trials show antidepressant effects.

Ashwagandha (Withania somnifera) withanolides modulate GABA-A receptors and NMDA receptors, supporting inhibitory neurotransmitter balance and reducing excitotoxicity. Multiple RCTs confirm anxiolytic and stress-reducing effects consistent with GABAergic modulation. Ayurvedic tradition has used it for centuries for nervous system support.

D-aspartic acid acts as an endogenous neuromodulator in the CNS, binding to and activating NMDA-type glutamate receptors and modulating release of multiple neurotransmitters including LHRH, GABA, alpha-MSH, and dopamine. It is also biosynthetically converted to NMDA in the brain. These roles are well-documented in animal and mechanistic human studies.

Bacopa monnieri (Brahmi) modulates acetylcholine, serotonin, dopamine, GABA, and glutamate via AChE inhibition, ChAT activation, and 5-HT reuptake regulation. Used in Ayurvedic medicine for over 1,400 years. Multiple RCTs in healthy adults confirm cognitive improvements consistent with multi-neurotransmitter modulation.

Choline is the essential dietary precursor for acetylcholine synthesis in the brain. Adequate choline is required for cholinergic neurotransmitter balance; deficiency impairs memory and cognitive function. The NIH recognizes choline as an essential nutrient with an adequate intake level. Dietary choline intake is directly linked to brain ACh availability.

Citicoline (CDP-choline) is a highly bioavailable choline donor that supports acetylcholine synthesis and upregulates dopamine receptor expression. Multiple RCTs in Alzheimer's disease and vascular cognitive impairment confirm its efficacy. It is approved as a pharmaceutical for cognitive disorders in several European countries.

Cocoa contains theobromine, caffeine, and small amounts of phenylethylamine and serotonin precursors that influence CNS neurotransmitter activity. Theobromine acts as an adenosine receptor antagonist and phosphodiesterase inhibitor. Clinical evidence for direct neurotransmitter modulation is primarily mechanistic with some RCT support for mood and fatigue outcomes.

Cowage seed contains 4–7% L-DOPA by weight, a direct dopamine precursor that crosses the blood–brain barrier. Human clinical studies confirm it raises dopamine, adrenaline, and noradrenaline in blood and seminal plasma. It also reduces prolactin via dopaminergic inhibition of pituitary lactotrophs.

Creatine monohydrate modulates key neurotransmitter systems, particularly serotonin and dopamine pathways. It is identified as a neuroprotective factor for dopaminergic neurons and its antidepressant-like effects are mediated through serotonin 5-HT1A receptor activation. Human pilot trials support creatine as an adjunct to antidepressant therapy.

D-Asp functions as an endogenous NMDA receptor agonist and neuromodulator that influences multiple neurotransmitter systems, including glutamatergic, dopaminergic, and GABAergic signaling. It regulates the release of dopamine, GABA, and hormones such as GnRH and oxytocin within the hypothalamus. Evidence is primarily from animal and mechanistic studies.

In vitro and animal studies show damiana extracts inhibit reuptake of dopamine, noradrenaline, and serotonin, and inhibit MAO-B. These actions collectively suggest modulation of monoamine neurotransmitter systems. All evidence is preclinical.

DHA is the predominant omega-3 in brain membranes, comprising ~40% of neuronal PUFAs and maintaining serotonin and dopamine receptor membrane environment. Deficiency reduces serotonin release and dopamine function. It is essential for normal neurotransmitter signal transduction and brain neurotransmitter development from infancy through adulthood.

DMAE is structurally similar to choline and is proposed to act as a precursor to choline and acetylcholine, modulating cholinergic neurotransmission. In vivo animal studies have directly confirmed that DMAE increases extracellular choline and acetylcholine in the medial prefrontal cortex. At low doses, DMAE promotes cholinergic transmission; at high doses it may also influence catecholaminergic systems. The extent of acetylcholine increase after typical oral doses in humans is not consistently demonstrated.

DHA modulates monoamine neurotransmitter systems in the brain. Animal studies show DHA supplementation significantly increases hypothalamic serotonin, 5-HIAA (serotonin metabolite), and dopamine. DHA also affects HPA axis hormones (corticosterone, ACTH) and arginine vasopressin, with implications for mood, stress response, and neurotransmitter homeostasis.

EPA is the omega-3 fatty acid with the strongest antidepressant evidence in meta-analyses, primarily via reducing neuroinflammation that suppresses serotonin synthesis. It inhibits PGE2 production that impairs tryptophan hydroxylase activity, and modulates HPA-axis cortisol which disrupts monoamine balance. Multiple independent RCTs confirm its antidepressant efficacy.

Fava beans directly supply L-DOPA, the immediate precursor to dopamine, norepinephrine, and epinephrine. Human studies confirm measurable plasma L-DOPA elevation after consumption, with downstream effects on dopaminergic neurotransmission. Fava beans' folate content also supports one-carbon methylation pathways required for monoamine neurotransmitter synthesis.

Fisetin modulates serotonin, noradrenaline, and dopamine systems in rodent brains: it increases 5-HT and NA in the frontal cortex and hippocampus, inhibits MAO-A, activates TrkB/BDNF, and supports dopaminergic neuron survival in Parkinson's models.

Folate, in its active form as l-methylfolate, crosses the blood-brain barrier and is required for the enzymatic synthesis of serotonin, dopamine, and norepinephrine. Low folate status has been associated with depleted cerebrospinal fluid serotonin and mood disturbances in clinical and population-based studies. However, folic acid supplementation at physiological doses in already-replete healthy individuals does not consistently improve neurotransmitter-related outcomes or mood. The relationship is most clinically relevant in folate-deficient populations and those with MTHFR polymorphisms that impair conversion of folic acid to active l-methylfolate.

Folinic acid supports neurotransmitter synthesis by feeding the folate/one-carbon cycle that generates SAM, the methyl donor required for biosynthesis of serotonin, dopamine, and norepinephrine. Cerebral folate deficiency reduces CSF 5-MTHF, directly impairing neurotransmitter synthesis pathways in the brain. This mechanism underpins folinic acid's investigated roles in depression, ASD, and related neuropsychiatric conditions.

GABA is the brain's primary inhibitory neurotransmitter; its deficiency is associated with depression, anxiety, and epilepsy. Major depressive disorder coincides with diminished brain GABA levels. Oral GABA supplementation may act via the enteric nervous system and gut-brain axis, with emerging evidence supporting peripheral and potentially central effects.

GE modulates multiple neurotransmitter systems: it upregulates GABA synthesis via GAD induction, modulates serotonin and dopamine levels, and regulates monoamine oxidase activity. These effects are documented across multiple animal studies.

Ginkgo biloba extract inhibits monoamine oxidase A and B, reducing catecholamine and serotonin degradation, and upregulates muscarinic acetylcholine receptors. Cochrane-referenced meta-analyses confirm cognitive and memory benefits in dementia, consistent with monoamine and cholinergic neurotransmitter support. Approved by German Commission E and WHO for age-related cognitive decline.

Glutamic acid (glutamate) is the principal excitatory neurotransmitter in the human CNS, acting through ionotropic (NMDA, AMPA, kainate) and metabotropic receptor families. It also serves as the direct biosynthetic precursor to the inhibitory neurotransmitter GABA via glutamic acid decarboxylase (GAD). Dysregulation of glutamatergic neurotransmission is implicated in a broad range of neuropsychiatric and neurological conditions. The glutamate-glutamine cycle between neurons and astrocytes is a core mechanism maintaining neurotransmitter balance.

Glycine is an inhibitory neurotransmitter in the spinal cord and brainstem, and a mandatory co-agonist at NMDA glutamate receptors in the brain. Multiple RCTs show high-dose glycine supplementation (30–60 g/day) significantly reduces negative symptoms in schizophrenia by enhancing NMDA receptor function and balancing glutamatergic neurotransmission.

Preclinical and some clinical evidence supports Gotu Kola's modulation of acetylcholine, GABA, serotonin, dopamine, and norepinephrine. These effects underpin its cognitive, anxiolytic, and mood-supporting properties. The herb also reduces cortisol, contributing to neurotransmitter balance under stress.

GPC (Alpha-GPC) is a highly bioavailable choline donor that raises brain acetylcholine levels and also modulates dopamine release. A 2003 multicenter RCT in 261 Alzheimer's patients confirmed cognitive improvements at 1,200 mg/day. It is approved as a pharmaceutical for cognitive disorders in Italy and other European countries.

Guarana's primary mechanism of action involves adenosine receptor antagonism by caffeine, which modulates the release of norepinephrine, dopamine, acetylcholine, glutamate, and serotonin. Chronic exposure to guarana seed extract has been shown in animal models to produce anxiolytic effects via dopaminergic and serotonergic neurotransmission. These effects underpin its cognitive and mood-related properties.

Huperzine A is a potent, reversible acetylcholinesterase inhibitor from Huperzia serrata maintaining acetylcholine levels in the brain. It also acts as a weak NMDA receptor antagonist. Multiple Chinese RCTs and meta-analyses confirm cognitive improvements in Alzheimer's disease and memory-impaired subjects.

Inositol serves as a second-messenger precursor in the phosphatidylinositol signaling cascade downstream of serotonin, dopamine, and muscarinic acetylcholine receptors. Multiple RCTs show that high-dose inositol (12–18 g/day) reduces panic disorder and OCD symptoms. It partially reverses the signaling deficit underlying the inositol depletion hypothesis of mood disorders.

Kanna alkaloids act on multiple neurotransmitter systems: they inhibit SERT and VMAT2-upregulate serotonin release, inhibit MAO-A, weakly inhibit noradrenaline and dopamine transporters, inhibit PDE4 (cAMP pathway), and activate GABA, opioid, and melatonin receptors preclinically. This broad but targeted modulation of monoamine and other signaling systems underpins most of kanna's observed effects.

Kavalactones modulate multiple neurotransmitter systems, including GABA-A receptor potentiation, inhibition of voltage-gated calcium and sodium channels, weak norepinephrine reuptake inhibition, reversible MAO-B inhibition, and variable dopamine effects. These mechanisms are supported by in vitro and in vivo pharmacological studies and underpin kava's documented anxiolytic effects in human trials.

L-asparagine is a biochemical precursor to aspartate, a recognized neuromodulator and putative excitatory neurotransmitter active in the CNS. Via asparagine synthetase, it participates in the interconversion between asparagine, aspartate, and glutamate, the principal excitatory neurotransmitters. This metabolic relationship is documented in peer-reviewed literature, though direct supplementation trials targeting neurotransmitter balance in humans are lacking.

Glutamine is the direct biosynthetic precursor to both glutamate and GABA in the brain, maintained through the astrocyte-neuron glutamine-glutamate-GABA cycle. Disruptions in this cycle are clinically documented in epilepsy and hepatic encephalopathy.

Glycine is itself a major inhibitory neurotransmitter in the spinal cord and brainstem, activating strychnine-sensitive glycine receptors (GlyRs). It is also an obligate co-agonist at excitatory NMDA glutamate receptors, making it unique in modulating both inhibitory and excitatory neurotransmission. High-dose glycine clinical trials have demonstrated restoration of NMDA receptor function in schizophrenia patients.

L-histidine is the sole dietary precursor of the neurotransmitter histamine in the brain, where histaminergic neurons from the tuberomammillary nucleus project throughout the entire CNS. Brain histamine regulates wakefulness, appetite, anxiety, stress responses, and the sleep-wake cycle, and histidine availability directly determines its synthesis rate.

L-methionine is the obligate precursor to SAMe, which methylates catecholamines and is required for synthesis of serotonin, dopamine, noradrenaline, and melatonin. SAMe-derived methyl groups are also needed for myelin formation (phosphatidylcholine synthesis) and epigenetic regulation of monoamine-related genes. Animal and human data confirm that L-methionine administration raises brain monoamine levels.

L-Phenylalanine is the essential amino acid precursor to tyrosine and, through tyrosine, to dopamine and norepinephrine. DL-phenylalanine also inhibits enkephalinase, preserving endorphin neurotransmitter levels. Clinical studies on DL-phenylalanine show antidepressant effects. It is foundational to the catecholamine neurotransmitter synthesis cascade.

L-serine is directly involved in the synthesis and modulation of multiple neurotransmitter systems. It is the obligate precursor to D-serine—an endogenous NMDA-receptor co-agonist—and to glycine, both of which critically regulate glutamatergic and glycinergic neurotransmission. L-serine also participates in the biosynthetic pathway for tryptophan, the precursor to serotonin.

L-Theanine, an amino acid from tea, crosses the blood-brain barrier and increases brain serotonin, dopamine, and GABA in animal studies. Human RCTs show it promotes alpha-wave relaxation without sedation and reduces stress-induced anxiety. It modulates multiple neurotransmitter systems relevant to inhibitory-excitatory balance.

L-Tryptophan is the sole dietary precursor to brain serotonin, and its availability directly regulates serotonin synthesis rate. Acute tryptophan depletion reliably lowers brain serotonin and worsens mood and cognition. Clinical trials provide evidence of efficacy in mood disorders, particularly in combination therapies.

L-Tyrosine is the direct amino acid precursor to dopamine, norepinephrine, and epinephrine. Multiple RCTs show it prevents catecholamine-dependent cognitive deficits under acute stressors including sleep deprivation and cold exposure. A 2015 systematic review of 15 controlled studies confirmed its neurotransmitter-supporting efficacy.

L. rhamnosus can synthesize and release GABA, modulating GABAergic neurotransmitter signaling via the gut-brain axis. It also influences brain BDNF levels, a key neurotrophin. Preclinical and mechanistic studies show that gut microbiota dysbiosis disrupts neurotransmitter signaling, and LGG can partially restore these pathways.

Lavender's key constituents linalool and linalyl acetate modulate multiple neurotransmitter systems. Linalool inhibits serotonin transporters (increasing synaptic serotonin), while linalyl acetate antagonizes NMDA receptors and enhances GABA action. Silexan also increases extracellular dopamine in rat brain and upregulates 5-HT1A receptor density in humans.

Lemon balm modulates multiple neurotransmitter systems. Rosmarinic acid and triterpenoids inhibit GABA transaminase, raising brain GABA. Compounds in the extract bind to nicotinic and muscarinic acetylcholine receptors. There is also in vitro evidence for monoamine oxidase A (MAO-A) inhibition, suggesting serotonergic effects. These mechanisms underpin its anxiolytic, sedative, and mood-modifying properties.

Animal studies demonstrate that Lion's Mane mycelium extract restores stress-depleted hippocampal serotonin, norepinephrine, and dopamine. Its erinacines and hericenones stimulate NGF synthesis, which supports the cholinergic system. Human evidence is indirect, mediated through observed mood and anxiety improvements in clinical trials.

Lithium modulates multiple neurotransmitter systems including serotonin, dopamine, glutamate, and norepinephrine. It increases synaptic serotonin, balances dopaminergic tone, and reduces glutamate-mediated excitotoxicity via NMDA receptor modulation. These effects are mediated primarily through GSK-3 inhibition and inositol depletion.

Magnesium is an essential mineral cofactor in dopamine synthesis (tyrosine hydroxylase) and a physiological blocker of NMDA glutamate receptor channels. Deficiency is linked to depression and anxiety. A 2017 RCT showed 248 mg/day magnesium significantly reduced both PHQ-9 depression and GAD-7 anxiety scores. It supports inhibitory-excitatory neurotransmitter balance.

Methylcobalamin is the neurologically active form of vitamin B12 that directly regenerates SAMe supporting serotonin, dopamine, and norepinephrine biosynthesis. It accumulates in brain tissue better than cyanocobalamin and directly participates in methionine synthase reactions. Japanese clinical studies confirm its role in CNS function and circadian neurotransmitter regulation.

Preclinical studies show POEE modulates multiple neurotransmitter systems: it inhibits acetylcholinesterase (boosting acetylcholine), activates dopamine D1 and beta-adrenergic receptors, and interacts with 5-HT2A serotonin receptors. This multi-target neurotransmitter profile is documented in peer-reviewed pharmacological studies.

NAC directly modulates glutamate homeostasis in the brain via the cystine-glutamate antiporter and indirectly modulates dopamine signaling. These mechanisms underpin its clinical investigation across multiple psychiatric and neurological conditions including schizophrenia, bipolar disorder, OCD, and addiction. Multiple clinical trials document neurochemical changes with NAC treatment.

Omega-3 fatty acids (EPA and DHA) determine neuronal membrane composition affecting serotonin, dopamine, and norepinephrine receptor density and signal transduction. Meta-analyses confirm EPA-predominant omega-3 supplementation significantly reduces depression symptoms. They also modulate neuroinflammation that impairs monoamine synthesis.

P-5-P is the biologically active coenzyme form of vitamin B6 that directly catalyzes serotonin, dopamine, and GABA production from their amino acid precursors without requiring hepatic activation. Its neurotransmitter synthesis cofactor role is documented in standard neurochemistry references. Pyridoxine-dependent epilepsy dramatically illustrates its role in GABA synthesis.

Passionflower's primary pharmacological mechanism centers on GABAergic modulation. Whole extract elicits direct GABA-A currents in hippocampal neurons in vitro, and flavonoids such as apigenin and chrysin act as partial agonists at benzodiazepine receptors. Beyond GABA, a 2025 systematic review identified broader non-GABAergic actions including monoaminergic pathways affecting dopamine, norepinephrine, and serotonin, and opioidergic systems. Indole alkaloids (harman, harmine) inhibit MAO enzymes, further elevating monoamine levels.

PC is the direct biochemical precursor for acetylcholine synthesis. As a major dietary choline source, adequate PC intake is required to sustain cholinergic neurotransmission. Declining brain PC levels with aging correlate with reduced ACh availability and cognitive decline.

Phosphatidylserine is a phospholipid essential for neuronal membrane function; it modulates acetylcholine and dopamine release. The US FDA has issued a qualified health claim for phosphatidylserine and reducing cognitive dysfunction risk. Multiple RCTs in elderly patients confirm improvements in memory and cognitive performance.

P. tenuifolia root modulates multiple neurotransmitter systems: it inhibits MAO-A and MAO-B (preserving dopamine, norepinephrine, serotonin), inhibits AChE (elevating acetylcholine), modulates GABA-A receptor subunits, and regulates NMDA receptors. This multi-system activity underpins its cognitive and mood-related effects.

Multiple peer-reviewed studies document that Polygala root modulates serotonin, dopamine, norepinephrine, GABA, and acetylcholine systems. These effects are supported by mechanistic in vitro and animal studies and are consistent with the cognitive and mood outcomes observed in human trials.

Pregnenolone and its sulfated metabolite are well-documented modulators of multiple neurotransmitter systems including GABA-A (negative allosteric modulation), NMDA/glutamate (positive modulation), dopamine, and acetylcholine. These actions underlie its broad neuropsychiatric relevance.

PQQ stimulates NGF production, which supports cholinergic and monoaminergic neurotransmitter systems. In Parkinson's disease animal models, PQQ preserved dopamine distribution and reduced dopaminergic neuron loss. No direct human RCT has measured neurotransmitter levels as a primary outcome.

Relora's active constituents modulate multiple neurotransmitter systems. Honokiol and magnolol are positive allosteric modulators of GABA-A receptors (PubMed 22445602), and Magnolia/Phellodendron fractions bind to the serotonin transporter. Berberine from Phellodendron inhibits monoamine oxidase-A, raising serotonin, dopamine, and norepinephrine in preclinical models. These actions collectively support a multi-system neurotransmitter-balancing profile.

Rhodiola rosea's active compounds salidroside and rosavins inhibit monoamine oxidase (MAO) and modulate serotonin, dopamine, and norepinephrine levels. Multiple RCTs support its use for mild-to-moderate depression and fatigue associated with neurotransmitter dysregulation. Traditionally used in Eurasian folk medicine for centuries.

Saffron (Crocus sativus) crocin and safranal inhibit reuptake of serotonin and dopamine, with multiple RCTs showing antidepressant efficacy comparable to SSRIs for mild-to-moderate depression. Traditional Persian medicine documented saffron's use for mood disorders for millennia. Independent RCTs and meta-analyses confirm its multi-neurotransmitter modulating effects.

SAMe is an endogenous methyl donor serving as the cofactor for rate-limiting steps in serotonin, dopamine, and norepinephrine biosynthesis. Low CNS SAMe levels are documented in depression. A 2002 AHRQ meta-analysis of 26 studies confirmed superior efficacy over placebo for depression. It has been prescribed in Europe for over 30 years.

Sceletium's alkaloids modulate multiple neurotransmitter systems: inhibiting serotonin reuptake (SERT), upregulating VMAT-2 to enhance monoamine vesicular release, mildly inhibiting MAO-A and AChE, inhibiting PDE4, and blocking CB1 receptors. This multi-target profile is well characterized pharmacologically.

A. julibrissin constituents modulate multiple neurotransmitter systems, including serotonin (via SERT inhibition and 5-HT1A agonism), dopamine, GABA, and HPA axis signalling. These mechanisms are directly demonstrated in pharmacological studies.

Skullcap directly modulates key neurotransmitter systems. Baicalin and baicalein from both species bind GABA-A receptors at the benzodiazepine site; S. lateriflora contains measurable free GABA; and multiple skullcap flavonoids bind serotonin 5-HT7 receptors. Preclinical evidence also shows monoamine oxidase-A inhibition, increasing serotonin and noradrenaline levels.

St. John's Wort (Hypericum perforatum) constituent hyperforin uniquely inhibits reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate simultaneously. Cochrane meta-analysis of 29 RCTs confirms efficacy for mild-to-moderate depression. Endorsed by German Commission E and WHO. Traditional use in European folk medicine is longstanding.

Taurine is a sulfur-containing beta-amino acid present at high CNS concentrations that acts as a weak GABA-A receptor agonist and modulates glycine, NMDA, and other neurotransmitter receptors. Peer-reviewed studies document its role in neurological disorders including epilepsy and depression. It is a recognized neuromodulator with GABAergic and inhibitory neurotransmitter activity.

TMG replenishes SAMe through the methionine cycle; SAMe is the obligate methyl donor for synthesis of serotonin, dopamine, and norepinephrine in the brain. By supporting SAMe availability, TMG indirectly sustains neurotransmitter synthesis and mood-related neurochemistry. Human studies show TMG augments SAMe's antidepressant effects, consistent with this pathway.

Valerian root's primary active constituent, valerenic acid, acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission without directly generating GABA. In vitro and in vivo studies further show inhibition of GABA-transaminase (reducing GABA breakdown), modulation of glutamate release via metabotropic glutamate receptors, and animal-study evidence of increased norepinephrine and dopamine following valepotriate treatment. These converging mechanisms establish a scientifically documented influence on multiple neurotransmitter systems.

A 2014 animal study in Psychiatry Research found that vanillin administered via the olfactory pathway elevated both serotonin and dopamine levels in rat brain tissue. Additionally, preclinical studies show vanillin protects dopaminergic neurons against inflammation-mediated death. Evidence is currently confined to animal models.

MP seeds are the richest known natural source of L-DOPA, which crosses the blood-brain barrier and converts to dopamine. Human clinical data in infertile men show MP treatment significantly raises blood and seminal plasma dopamine, adrenaline, and noradrenaline levels. Dopamine also inhibits pituitary prolactin release, modulating the downstream catecholamine cascade. Leaves additionally contain serotonin (5-HT) and its precursor 5-HTP.

Thiamine is directly required for the synthesis of acetylcholine, modulates GABA and glutamate levels, and has inhibitory activity against acetylcholinesterase. Deficiency causes measurable disruptions in acetylcholine, GABA, glutamate, aspartate, and serotonin levels across neuronal tissues.

Vitamin B12 is required for the one-carbon cycle generating SAMe for neurotransmitter synthesis. B12 deficiency causes neurological symptoms including depression and cognitive impairment through impaired SAMe-dependent methylation of neurotransmitters. Supplementation in deficient individuals reliably restores neurotransmitter synthesis capacity.

Niacin spares tryptophan from the kynurenine pathway, preserving its availability for serotonin synthesis. It is also a precursor to NAD+, supporting energy metabolism in neurotransmitter-producing neurons. Hoffer's orthomolecular trials proposed high-dose niacin for dopamine-serotonin balance in schizophrenia. Pellagra (niacin deficiency) causes dementia confirming its necessity for CNS function.

Niacinamide (nicotinamide) spares tryptophan for serotonin synthesis and serves as NAD+ precursor supporting neuronal energy for neurotransmitter production. Animal studies show nicotinamide acts at GABA-A/benzodiazepine sites with anxiolytic activity. Orthomolecular medicine has documented its use for neurotransmitter-related psychiatric conditions.

Vitamin B6, as pyridoxal-5-phosphate (PLP), is the essential coenzyme for decarboxylation reactions producing serotonin (from 5-HTP), dopamine (from L-DOPA), and GABA (from glutamate). Without PLP, all three pathways are impaired. Deficiency is associated with depression and anxiety. Recognized in NCBI Basic Neurochemistry as a critical neurotransmitter synthesis cofactor.

Folate is essential for generating SAMe, the methyl donor for neurotransmitter synthesis. Folate deficiency is among the most replicated nutritional associations with depression. MTHFR gene variants link folate metabolism to neurotransmitter imbalance. Meta-analyses confirm lower serum folate in depression; adjunctive folate improves antidepressant outcomes.

5-MTHF is the biologically active folate form that directly regenerates SAMe, supporting serotonin, dopamine, and norepinephrine synthesis. Clinical RCTs demonstrate adjunctive 15 mg/day L-methylfolate significantly improves treatment-resistant depression. It bypasses MTHFR polymorphisms affecting 25–40% of the population.

Mechanistic studies consistently show Bacopa monnieri modulates multiple neurotransmitter systems including serotonin (5-HT), dopamine, acetylcholine, and GABA. These effects are well-characterized in vitro and in animal models and are proposed to underlie its cognitive and mood effects seen in human trials.

Zinc is an essential trace mineral required as a cofactor in GABA-synthesizing enzyme (GAD), tryptophan hydroxylase, and monoamine oxidase. Meta-analyses document significantly lower serum zinc in depressed patients. RCTs show zinc augmentation of antidepressant therapy improves treatment outcomes, consistent with neurotransmitter synthesis support.